

1 August 2024

Hereditary Angioedema (HAE) and Acquired HAE Treatment

1. The current total number of patients with Hereditary Angioedema (HAE) types 1, 2, normal C1, and Acquired HAE assisted by your institution.

Our most recent figures as of 2023:

| | |
|-------------------------------------|----|
| HAE1 | 31 |
| HAE2 | <5 |
| Acquired HAE | <5 |
| HAE with normal C1 inhibitor | 0 |

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. The volume of medication dispensed and/or consumed from January 1st, 2024, to June 30th, 2024, for each product below. If it is more convenient to specify the number of vials, pre-filled syringes, or tablets, that would also be very helpful.

List of Medications:

| | |
|--|---|
| Ianadelumab (Takzhyro - SC) | 16 x 300mg pre-filled syringe |
| pdC1-inhibitor (Cinryze - IV) | 338 x 500mg Soln for Infusion 2 Vial Pack |
| pdC1-inhibitor (Berinert - IV and SC) | 20 x 1500iu amps and 63 x 500iu amps |
| rC1-inhibitor (Ruconest - IV) | Zero |
| icatibant (Firazyr and generic - SC) | 84 x 30mg prefilled syringe |
| berotralstat (Orladeyo) | 4 x 150mg (packs of 28) |